PubMed Health⌕ Search

Biomedical subjects

H T Power

Publications and source records attributed to H T Power.

12 recordsLinked to original sources
PubMed2001

Degenerative mucinotic mural folliculitis in cats.

A novel form of mural folliculitis is described in seven cats. Clinically, all cats exhibited generalized alopecia with scaling or crusting that was more pronounced over the head, neck, and shoulders. The face and muzzle of all cats was unusually thickened. Six of seven cats were progressively lethargic but did not demonstrate any other consistent systemic abnormalities. Histologically, there was severe mixed inflammation of the wall of the follicular isthmus in all cats, accompanied by some follicular destruction in five cats. Sebaceous glands were not affected. All cats had variable, but often striking, follicular mucin deposition, as well as epidermal hyperkeratosis and crusting. The cause of the severe mural folliculitis was not identified, and all cats responded poorly to immunomodulating therapy. Follicular mucinosis may be a nonspecific finding, likely reflective of the follicular lymphocytic milieu, and does not always herald follicular lymphoma.

Alopecia↗
PubMed1995

Selected feline eosinophilic skin diseases.

Eosinophilic plaque and mosquito-bite dermatitis are recognized hypersensitivity reactions. The pathogenesis of eosinophilic granuloma and indolent ulcer are not as clearly understood. Each of these syndromes is distinctive from a clinical and histopathologic view point. Accurate diagnosis depends on history, physical findings, and histopathologic evaluation. Understanding of feline dermatology will be furthered by including these syndromes in a broader grouping that encompasses all the feline eosinophilic dermatoses.

Animals↗
PubMed1992

Use of etretinate for treatment of primary keratinization disorders (idiopathic seborrhea) in cocker spaniels, west highland white terriers, and basset hounds.

An open clinical trial was used to evaluate the synthetic retinoid, etretinate, for treatment of idiopathic seborrhea in Cocker Spaniels, West Highland White Terriers, and Basset Hounds. Clinical and histologic improvement was seen in the Cocker Spaniels. Etretinate had no beneficial effect on the skin disease of the West Highland White Terriers or the Basset Hounds. Etretinate treatment did not alter the type or degree of otitis externa. Clinical side effects were minimal. Relevant laboratory abnormalities were not detected.

Animals↗
PubMed1992

Clinical evaluation of etretinate for the treatment of canine solar-induced squamous cell carcinoma and preneoplastic lesions.

BACKGROUND: Tumors of the skin and subcutaneous tissue account for 30% of all canine neoplasms. Canine solar-induced squamous cell carcinoma (SCC) is the most frequently reported canine cutaneous neoplasm. OBJECTIVE: The purpose of this study was to provide preliminary observations on the safety and efficacy of etretinate for the treatment of solar-induced SCC and associated preneoplastic lesions in dogs. METHODS: Etretinate was administered to 10 dogs at 1 mg/kg twice daily for a minimum of 90 days. RESULTS: Clinically, two dogs showed complete resolution of their preneoplastic lesions, three dogs had partial responses, two dogs maintained stable disease, and three dogs showed progression of lesions after 90 days of etretinate administration. Three dogs showed histologic improvement, four dogs showed no changes, and three dogs showed evidence of progressing SCC. Treatment-related biochemical abnormalities included reversible hypertriglyceridemia and transient serum liver enzyme elevations in three dogs. CONCLUSION: These preliminary findings suggest that etretinate, at the dosage administered, may provide therapeutic efficacy for solar-induced preneoplastic lesions in the dog, particularly for those multifocal lesions not easily managed by local methods of therapy.

Animals↗
PubMed1990

Synthetic retinoids in veterinary dermatology.

The synthetic retinoids, isotretinoin (Accutane) and etretinate (Tegison) are vitamin A analogs. They affect epithelial differentiation and thus have potential for therapy for disorders of epithelial maturation such as keratinization defects of cutaneous neoplasia. The pharmacology, indications for use, clinical experience, potential toxicities, and recommended monitoring of these drugs are discussed.

Animals↗
PubMed1983

Facial and vestibulocochlear nerve disease in six horses.

In 6 horses, clinical signs of illness implicated a lesion involving the facial and vestibulocochlear nerves. One horse had signs of otitis externa. Five horses had radiographic changes primarily involving periosteal bony proliferation of the stylohyoid bone at its articulation with the temporal bone. Five horses improved with antibiotic therapy. Otitis media-interna was found at necropsy of one horse.

Ampicillin↗
PubMed1983

Bacterial endocarditis in adult dairy cattle.

Thirty-one cases of bacterial endocarditis in adult dairy cows were reviewed. Clinical signs were reflective of the stage of the disease. Recurrent or persistent fever, tachycardia and a pounding heartbeat or systolic murmur, polypnea, and lameness were typical. With chronicity, weight loss and poor production developed. The end stage was congestive heart failure. Neutrophilia was typical in early cases. Low-grade anemia and high total serum globulin content developed with chronicity and seemed to be negative prognostic signs. Corynebacterium pyogenes was the organism most frequently identified by blood culture or at necropsy. Twenty cows were necropsied and 2 cows were sent to slaughter. Nine cows in which the diagnosis was made early in the course of the disease responded to long-term penicillin therapy.

Animals↗
PubMed1982

Use of a gold compound for the treatment of pemphigus foliaceus in a foal.

A 4-month-old foal was examined because of generalized exfoliative dermatitis, with thick scales, extensive crusting, and oozing of serum. A diagnosis of pemphigus foliaceus was made by histologic and immunopathologic examinations of skin biopsy specimens. The foal was treated with a gold compound, aurothioglucose (1 mg/kg once weekly for 14 weeks). For the initial 5 weeks, high-dose glucocorticoid treatments also was used. The skin disorder resolved entirely after 12 weeks of treatment.

Animals↗